|
1
|
Beiki O, Hall P, Ekbom A and Moradi T:
Breast cancer incidence and case fatality among 4.7 million women
in relation to social and ethnic background: A population-based
cohort study. Breast Cancer Res. 14:R52012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buijs JT and van der Pluijm G: Osteotropic
cancers: From primary tumor to bone. Cancer Lett. 273:177–193.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang J and Xu Q: Differences of
osteoblastic bone metastases and osteolytic bone metastases in
clinical features and molecular characteristics. Clin Transl Oncol.
17:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuchuk I, Hutton B, Moretto P, Ng T,
Addison CL and Clemons M: Incidence, consequences and treatment of
bone metastases in breast cancer patients-Experience from a single
cancer centre. J Bone Oncol. 2:137–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harries M, Taylor A, Holmberg L, Agbaje O,
Garmo H, Kabilan S and Purushotham A: Incidence of bone metastases
and survival after a diagnosis of bone metastases in breast cancer
patients. Cancer Epidemiol. 38:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oakman C, Viale G and Di Leo A: Management
of triple negative breast cancer. Breast. 19:312–321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morris GJ, Naidu S, Topham AK, Guiles F,
Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, et al:
Differences in breast carcinoma characteristics in newly diagnosed
African-American and Caucasian patients: A single-institution
compilation compared with the National Cancer Institute's
Surveillance, Epidemiology, and End Results database. Cancer.
110:876–884. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katz H and Alsharedi M: Immunotherapy in
triple-negative breast cancer. Med Oncol. 35:132017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ji HF, Li XJ and Zhang HY: Natural
products and drug discovery. Can thousands of years of ancient
medical knowledge lead us to new and powerful drug combinations in
the fight against cancer and dementia? EMBO Rep. 10:194–200.
2009.PubMed/NCBI
|
|
16
|
Chowdhury AR, Mandal S, Mittra B, Sharma
S, Mukhopadhyay S and Majumder HK: Betulinic acid, a potent
inhibitor of eukaryotic topoisomerase I: Identification of the
inhibitory step, the major functional group responsible and
development of more potent derivatives. Med Sci Monit.
8:BR254–BR265. 2002.PubMed/NCBI
|
|
17
|
Viji V, Helen A and Luxmi VR: Betulinic
acid inhibits endotoxin-stimulated phosphorylation cascade and
pro-inflammatory prostaglandin E(2) production in human peripheral
blood mononuclear cells. Br J Pharmacol. 162:1291–1303. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Melo CL, Queiroz MG, Arruda Filho AC,
Rodrigues AM, de Sousa DF, Almeida JG, Pessoa OD, Silveira ER,
Menezes DB, Melo TS, et al: Betulinic acid, a natural pentacyclic
triterpenoid, prevents abdominal fat accumulation in mice fed a
high-fat diet. J Agric Food Chem. 57:8776–8781. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Genet C, Strehle A, Schmidt C, Boudjelal
G, Lobstein A, Schoonjans K, Souchet M, Auwerx J, Saladin R and
Wagner A: Structure-activity relationship study of betulinic acid,
a novel and selective TGR5 agonist, and its synthetic derivatives:
Potential impact in diabetes. J Med Chem. 53:178–190. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Sá MS, Costa JF, Krettli AU, Zalis MG,
Maia GL, Sette IM, Câmara CA, Filho JM, Giulietti-Harley AM,
Ribeiro Dos Santos R, et al: Antimalarial activity of betulinic
acid and derivatives in vitro against Plasmodium falciparum and in
vivo in P. berghei-infected mice. Parasitol Res. 105:275–279. 2009.
View Article : Google Scholar
|
|
21
|
Aisha AF, Ismail Z, Abu-Salah KM, Siddiqui
JM, Ghafar G and Abdul Majid AM: Syzygium campanulatum korth
methanolic extract inhibits angiogenesis and tumor growth in nude
mice. BMC Complement Altern Med. 13:1682013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fulda S: Betulinic acid: A natural product
with anticancer activity. Mol Nutr Food Res. 53:140–146. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu J, Li Z, Luo J, Yang F, Liu T, Liu M,
Qiu WW and Tang J: Synthesis and biological evaluation of
heterocyclic ring-fused betulinic acid derivatives as novel
inhibitors of osteoclast differentiation and bone resorption. J Med
Chem. 55:3122–3134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liotta LA and Kohn EC: The
microenvironment of the tumour-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: From dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sawant A, Hensel JA, Chanda D, Harris BA,
Siegal GP, Maheshwari A and Ponnazhagan S: Depletion of
plasmacytoid dendritic cells inhibits tumor growth and prevents
bone metastasis of breast cancer cells. J Immunol. 189:4258–4265.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan W, Zhang W, Strasner A, Grivennikov S,
Cheng JQ, Hoffman RM and Karin M: Tumour-infiltrating regulatory T
cells stimulate mammary cancer metastasis through RANKL-RANK
signalling. Nature. 470:548–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sawant A and Ponnazhagan S:
Myeloid-derived suppressor cells as osteoclast progenitors: A novel
target for controlling osteolytic bone metastasis. Cancer Res.
73:4606–4610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sung B, Pandey MK, Ahn KS, Yi T,
Chaturvedi MM, Liu M and Aggarwal BB: Anacardic acid (6-nonadecyl
salicylic acid), an inhibitor of histone acetyltransferase,
suppresses expression of nuclear factor-kappaB-regulated gene
products involved in cell survival, proliferation, invasion, and
inflammation through inhibition of the inhibitory subunit of
nuclear factor-kappaBalpha kinase, leading to potentiation of
apoptosis. Blood. 111:4880–4891. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hou T, Lou Y, Li S, Zhao C, Ji Y, Wang D,
Tang L, Zhou M, Xu W, Qian M, et al: Kadsurenone is a useful and
promising treatment strategy for breast cancer bone metastases by
blocking the PAF/PTAFR signaling pathway. Oncol Lett. 16:2255–2262.
2018.PubMed/NCBI
|
|
31
|
Li Z, Huang J, Wang F, Li W, Wu X, Zhao C,
Zhao J, Wei H, Wu Z, Qian M, et al: Dual targeting of Bile Acid
Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) prevents
estrogen-dependent bone loss in mice. J Bone Miner Res. 34:765–776.
2019.PubMed/NCBI
|
|
32
|
van der Heide V, Möhnle P, Rink J, Briegel
J and Kreth S: Down-regulation of MicroRNA-31 in CD4+ T cells
contributes to immunosuppression in human sepsis by promoting TH2
skewing. Anesthesiology. 124:908–922. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pusztai L, Karn T, Safonov A, Abu-Khalaf
MM and Bianchini G: New strategies in breast cancer: Immunotherapy.
Clin Cancer Res. 22:2105–2110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McArthur HL and Page DB: Immunotherapy for
the treatment of breast cancer: Checkpoint blockade, cancer
vaccines, and future directions in combination immunotherapy. Clin
Adv Hematol Oncol. 14:922–933. 2016.PubMed/NCBI
|
|
36
|
Schalper KA, Velcheti V, Carvajal D,
Wimberly H, Brown J, Pusztai L and Rimm DL: In situ tumor PD-L1
mRNA expression is associated with increased TILs and better
outcome in breast carcinomas. Clin Cancer Res. 20:2773–2782. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sinha P, Clements VK and Ostrand-Rosenberg
S: Reduction of myeloid-derived suppressor cells and induction of
M1 macrophages facilitate the rejection of established metastatic
disease. J Immunol. 174:636–645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: Plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mullauer FB, Kessler JH and Medema JP:
Betulinic acid, a natural compound with potent anticancer effects.
Anticancer Drugs. 21:215–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Petrie RJ and Yamada KM: At the leading
edge of three-dimensional cell migration. J Cell Sci.
125:5917–5926. 2012.PubMed/NCBI
|
|
42
|
Akhshi TK, Wernike D and Piekny A:
Microtubules and actin crosstalk in cell migration and division.
Cytoskeleton (Hoboken). 71:1–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Goode BL and Eck MJ: Mechanism and
function of formins in the control of actin assembly. Annu Rev
Biochem. 76:593–627. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kovar DR: Molecular details of
formin-mediated actin assembly. Curr Opin Cell Biol. 18:11–17.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Aragona M, Panciera T, Manfrin A, Giulitti
S, Michielin F, Elvassore N, Dupont S and Piccolo S: A mechanical
checkpoint controls multicellular growth through YAP/TAZ regulation
by actin-processing factors. Cell. 154:1047–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu FX and Guan KL: The Hippo pathway:
Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang Y, Xiao Y, Dong Q, Ouyang W and Qin
Q: Neferine in the Lotus Plumule Potentiates the Antitumor Effect
of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro. J
Food Sci. 84:904–910. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yoneda T, Michigami T, Yi B, Williams PJ,
Niewolna M and Hiraga T: Use of bisphosphonates for the treatment
of bone metastasis in experimental animal models. Cancer Treat Rev.
25:293–299. 1999. View Article : Google Scholar : PubMed/NCBI
|
